Spiess B M
Veterinary Ophthalmology Service, Equine Department, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich, Switzerland.
Equine Vet J Suppl. 2010 Mar(37):50-6. doi: 10.1111/j.2042-3306.2010.tb05635.x.
Equine recurrent uveitis (ERU) has always been and still is an important disease with a significant impact on the horse industry in Europe, with a prevalence of 8-10%. The need to understand and manage the disease has spurred the development of veterinary ophthalmology in general, although the aetiology of the disease remains the subject of intense discussion. It is most probably an autoimmune disease triggered, at least in Europe, in the majority of cases by Leptospira spp. The therapy of ERU has evolved over the centuries from various methods of bloodletting to rational medical therapy using mydriatics and steroidal and nonsteroidal anti-inflammatory drugs, to surgical therapies, such as vitrectomy or implantation of cyclosporin-releasing devices. In Europe, pars plana vitrectomy in horses testing positive for Leptospira spp. appears to be the most successful form of therapy at the present time.
马复发性葡萄膜炎（ERU）一直以来都是且至今仍然是一种重要疾病，对欧洲的养马业有重大影响，患病率为8% - 10%。尽管该疾病的病因仍是激烈讨论的主题，但总体上对理解和管理该疾病的需求推动了兽医眼科学的发展。它很可能是一种自身免疫性疾病，至少在欧洲，大多数病例是由钩端螺旋体属引发的。几个世纪以来，ERU的治疗方法从各种放血方法发展到使用散瞳剂、甾体和非甾体抗炎药的合理药物治疗，再到手术治疗，如玻璃体切除术或植入释放环孢素的装置。在欧洲，对钩端螺旋体属检测呈阳性的马匹进行的睫状体平坦部玻璃体切除术似乎是目前最成功的治疗方式。
